Home / Executive Moves / Horacio Rozanski to Succeed Ralph Shrader as Booz Allen CEO

Horacio Rozanski to Succeed Ralph Shrader as Booz Allen CEO

Horacio Rozanski
Horacio Rozanski

Horacio Rozanski, president and chief operating officer at Booz Allen Hamilton (NYSE: BAH), will succeed the retiring Ralph Shrader as chief executive of the McLean, Va.-based consulting firm on Jan. 1, 2015.

Shrader, a 40-year company veteran, will keep his role as chairman of the board of directors after he officially retires from the CEO role on Dec. 31 of this year, Booz Allen announced Monday.

He has led Booz Allen as chief executive for the past 15 years, leading the firm through its initial public offering and a commercial business spinoff, among other corporate initiatives.

Ralph Shrader
Ralph Shrader

Rozanski has been with Booz Allen since 1992 and started his career as a marketing and channel strategy consultant before holding the positions of vice president, chief personnel officer, and chief strategy and talent officer between 1999 and 2010.

“I have known Horacio since he was a rising partner in Booz Allen’s consumer products practice and had developed a strong reputation for business strategy and client service, ” Shrader said.

“In his client-facing and internal leadership roles, Horacio has gained the respect of management and staff at all levels, and of the Board and investment community, ” he added.

Rozanski spearheads a Vision 2020 strategy at the company with the goal of expanding the firm’s innovation portfolio, international market footrprint and professional development programs.

He holds a bachelor of business administration degree from the University of Wisconsin Eau Claire and an M.B.A. degree from the University of Chicago.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.